Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program

Marc Arbyn1 and Philip E. Castle2,3

Abstract

In 2016, the Netherlands will switch, as first European country, from cytology-based to HPV-based cervical cancer screening, with cytology triage for those with a positive HPV test. The new Dutch program includes sending self-sampling devices to women who do not respond to an invitation to have a cervical sample taken by their general practitioner. The cost-effectiveness of this additional strategy will depend on its capacity to recruit nonscreened women and in particular those at increased risk of cervical (pre) cancer, the possible switch of previous responders to self-sampling, the accuracy and cost of the HPV assay–self-sampler combination, and the compliance of women being self-sample HPV-positive with further follow-up. Validated PCR-based assays, detecting high-risk HPV DNA, are as accurate on self-samples as on clinician-collected samples. On the contrary, HPV assays, based on signal amplification, are less sensitive and specific on self-samples. The introduction of self-sampling strategies should be carefully prepared and evaluated in pilot studies integrated in well-organized settings before general rollout. Opt-in procedures involving a request for a self-sampler may reduce response rates. Therefore, an affordable device that can be included with the invitation to all nonattendees may yield a stronger effect on participation.

In this issue of Cancer Epidemiology, Biomarkers & Prevention, Rozemeijer and colleagues (1) simulate the cost-effectiveness of HPV testing on samples taken by the woman herself. There is now substantial evidence that high-risk human papillomavirus (hrHPV)-based screening is more effective in reducing the incidence of cervical precancer and cancer than cytology-based screening (2, 3). Several countries have switched or are in the process of switching to hrHPV testing for primary cervical cancer screening, taking advantage of the greater reassurance of a negative hrHPV test than a negative Pap test and permitting longer intervals between screens (2, 3).

Another advantage of using HPV testing is that, contrary to cytology, it can be done using a vaginal sample collected by the woman herself. Offering women a device to self-sample can increase the population coverage by reaching those who are reluctant to participate in the regular screening program that requires clinic-based visits and pelvic examinations (4).

In 2016, health authorities in the Netherlands plan to switch to HPV-based screening for women ages 30 to 60 years for 5 screens in a lifetime at ages 30, 35, 40, 50, and 60 years. All women ages 30 to 60 years will be invited to contact their general practitioner to have a cervical Pap specimen collected into liquid-based cytology (LBC) medium, which will be tested for hrHPV DNA. Reflex cytology will be done on hrHPV positives and, if negative, a follow-up LBC 6 to 12 months later will be conducted. Women with an abnormal reflex or follow-up LBC will be referred to colposcopy. Women who do not respond to the invitation will be given the opportunity to request a free self-sampling kit to be sent to their home address, with the self-sample being tested by the same hrHPV test used for clinician-collected specimen (5, 6).

In this issue of CEBP, Rozemeijer and colleagues (1) simulated the potential advantages, costs, and harms associated with including self-sampling as part of the new Dutch organized program over plausible ranges of influencing factors. As noted by Rozemeijer and colleagues (1), approximately 50% of the cervical cancer that occurs in the Netherlands occurs in approximately 30% of women who do not attend screening regularly or at all, a similar issue in many high-resource countries (7). Strategies that include offering self-sampling to nonattendees generally are cost-effective, unless hrHPV testing on self-samples would be substantially less accurate and regularly attending women should switch to self-sampling and the response of nonattendees to use self-samplers would be poor (1).

The article by Rozemeijer and colleagues (1) raises some important considerations with regard to the introduction of self-sampling into cervical cancer screening programs to reach the nonattendees. First, the effectiveness of offering self-samplers will, in the first place, depend on its capacity to recruit unscreened women and in particular those at increased risk of cervical (pre)cancer. In trials, the response rate among underscreened women who received invitations, including self-samplers, varied widely between settings ranging from 6% (8) to 31% (9), which was on average 2.1 times higher (95% CI, 1.3–3.5) than in the control groups who received a conventional reminder letter (4). In two trials, conducted in Italy and Sweden, women were sent a

1 Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium. 2 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York. 3 Global Coalition Against Cervical Cancer, Arlington, Virginia.

Corresponding Author: Marc Arbyn, Belgian Cancer Centre, Scientific Institute of Public Health, Juliette Wytswaenstreet 14, B1050 Brussels, Belgium. Phone: 32-2-642-50-21; Fax: 32-2-642-54-10; E-mail: marc.arbyn@wiv-isp.be

doi: 10.1158/1055-9965.EPI-14-1417

©2015 American Association for Cancer Research.

www.aacrjournals.org
self-sampler if they confirmed their wish to receive one (10, 11). The pooled difference in participation rates between the opt-in self-sampling arm and the control arm of conventional reminder letter was not significantly different from zero (1%; 95% CI, −4% to 5%; pooled from refs. 11, 12). These findings suggest that opt-in strategies, which may reduce the waste of unused self-samplers, compromise the potential gain in population coverage. It should be underlined that self-sampling strategies will run much more efficiently in well-monitored settings with up-to-date registries covering organized and opportunistic screening, allowing a precise targeting of women who did not have a screen test over the last years and avoiding sending self-samplers to women already screened.

A second issue is the performance and acceptability of the device. A recent meta-analysis on accuracy of HPV testing on self-samples did not reveal device effects (12). Very few studies compared the relative accuracy of different devices. Recently, a trial conducted in the Netherlands showed similar performance of two devices speciﬁcally designed for vaginal self-sampling (13). Whether more simple and cheap self-samplers might be as appropriate, acceptable, and accurate as the more expensive specially designed tools is a challenging research question. Such inexpensive, user-friendly devices, which could be included in invitation letters to nonattendees, relieve the economical need for opt-in procedures.

Third, the success of a self-sampling strategy depends on the clinical performance of the hrHPV testing of the self-sample. The aforementioned meta-analysis demonstrated that the sensitivity and speciﬁcity of HPV testing are similar on self- as on clinician-taken samples when validated PCR tests are used but not when signal amplification-based HPV assays are applied (12). The conclusions of this meta-analysis remain unchanged after the addition of recently published studies (12, 14–16). The pooled relative sensitivity and specificity of 19 studies using HC2 (Qiagen) in self- versus clinician-collected samples were 0.86 (95% CI, 0.82–0.91) and 0.96 (95% CI, 0.93–0.98), respectively (see Fig. 1). In one study using Cervista (Hologic), the relative accuracy values were 0.76 (95% CI, 0.70–0.83) for sensitivity and 0.95 (95% CI, 0.94–0.96) for speciﬁcity. On the contrary, in nine studies using validated PCR-based HPV DNA assays, the relative sensitivity and speciﬁcity were 0.98 (95% CI, 0.95–1.02) and 1.02 (0.94–1.09), respectively (see Fig. 2). Rozemeijer and colleagues (1) showed that the use of an HPV assay with lower sensitivity and speciﬁcity on self-samples would make the new Dutch screening program less effective, less cost-effective, and more vulnerable to a possible switch of previous responders to self-sampling.

A forth issue is the management of hrHPV-positive results because most hrHPV-positive women will not have cervical precancer and cancer. Cytology, as reﬂex test on hrHPV-positive specimens, is rather inaccurate on self-samples. Therefore, women with an hrHPV-positive self-sample will need to contact a clinician to have a Pap smear taken to identify the women who have to be referred for further diagnostic workup. This step might be particularly problematic for this hard-to-reach target population. Compliance with further follow-up among self-sample hrHPV-positive women varied in trials between 41% (17) and 100% (11, 18). Having a molecular method allowing accurate reﬂex triage on the same self-sample would offer a major advantage, avoiding an additional visit and reducing the burden for further follow-up. Candidate triage methods are the currently available genotyping for HPV16/18 (19), which account for approximately 70% of the cancer risk, and, in the future, maybe also methylation markers of certain viral or human genes (20), which both are associated with progressing infections.

<table>
<thead>
<tr>
<th>Study</th>
<th>RR (95% CI)</th>
<th>Study</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hillemans, 1999</td>
<td>1.00 (0.88–1.13)</td>
<td>Hillemans, 1999</td>
<td>0.85 (0.74–0.98)</td>
</tr>
<tr>
<td>Sellors, 2000</td>
<td>0.88 (0.79–0.98)</td>
<td>Sellors, 2000</td>
<td>1.03 (0.82–1.28)</td>
</tr>
<tr>
<td>Wright, 2000</td>
<td>0.79 (0.63–0.98)</td>
<td>Wright, 2000</td>
<td>0.99 (0.95–1.02)</td>
</tr>
<tr>
<td>Belinson, 2001</td>
<td>0.87 (0.78–0.96)</td>
<td>Belinson, 2001</td>
<td>1.01 (0.98–1.03)</td>
</tr>
<tr>
<td>Salmeron, 2003</td>
<td>0.77 (0.67–0.88)</td>
<td>Salmeron, 2003</td>
<td>0.98 (0.97–0.99)</td>
</tr>
<tr>
<td>Giranielli, 2006</td>
<td>0.84 (0.69–1.04)</td>
<td>Giranielli, 2006</td>
<td>0.97 (0.95–0.99)</td>
</tr>
<tr>
<td>Holanda, 2006</td>
<td>1.00 (0.72–1.39)</td>
<td>Holanda, 2006</td>
<td>0.92 (0.87–0.96)</td>
</tr>
<tr>
<td>Szarewski, 2007</td>
<td>0.81 (0.65–1.02)</td>
<td>Szarewski, 2007</td>
<td>0.97 (0.93–1.01)</td>
</tr>
<tr>
<td>Bhatia, 2009</td>
<td>0.89 (0.74–1.07)</td>
<td>Bhatia, 2009</td>
<td>0.96 (0.92–1.00)</td>
</tr>
<tr>
<td>Balasubramanian, 2010</td>
<td>0.90 (0.82–1.00)</td>
<td>Balasubramanian, 2010</td>
<td>0.94 (0.90–0.98)</td>
</tr>
<tr>
<td>Taylor, 2011</td>
<td>0.86 (0.75–0.97)</td>
<td>Taylor, 2011</td>
<td>0.80 (0.77–0.82)</td>
</tr>
<tr>
<td>Longatto-F, 2012</td>
<td>0.71 (0.62–0.83)</td>
<td>Longatto-F, 2012</td>
<td>1.01 (1.00–1.02)</td>
</tr>
<tr>
<td>Zhao, 2012a</td>
<td>0.87 (0.72–1.04)</td>
<td>Zhao, 2012a</td>
<td>0.97 (0.94–1.01)</td>
</tr>
<tr>
<td>Zhao, 2012b</td>
<td>0.62 (0.57–1.02)</td>
<td>Zhao, 2012b</td>
<td>0.99 (0.95–1.02)</td>
</tr>
<tr>
<td>Zhao, 2012c</td>
<td>0.94 (0.76–1.16)</td>
<td>Zhao, 2012c</td>
<td>0.98 (0.96–1.01)</td>
</tr>
<tr>
<td>Jentschke, 2013a</td>
<td>0.77 (0.57–1.04)</td>
<td>Jentschke, 2013a</td>
<td>0.48 (0.29–0.79)</td>
</tr>
<tr>
<td>Jentschke, 2013b</td>
<td>0.93 (0.62–1.40)</td>
<td>Jentschke, 2013b</td>
<td>0.94 (0.61–1.46)</td>
</tr>
<tr>
<td>Neves, 2013 [14]</td>
<td>0.73 (0.54–0.98)</td>
<td>Neves, 2013 [14]</td>
<td>0.98 (0.96–1.00)</td>
</tr>
<tr>
<td>Zhao, 2013 [15]</td>
<td>0.96 (0.90–1.02)</td>
<td>Zhao, 2013 [15]</td>
<td>0.96 (0.95–0.97)</td>
</tr>
<tr>
<td>Subtotal (F = 53.8%, P = 0.003)</td>
<td>0.86 (0.82–0.91)</td>
<td>Subtotal (F = 93.5%, P = 0.000)</td>
<td>0.96 (0.93–0.98)</td>
</tr>
<tr>
<td>Cervista, Belinson, 2012</td>
<td>0.76 (0.70–0.83)</td>
<td>Cervista, Belinson, 2012</td>
<td>0.95 (0.94–0.96)</td>
</tr>
<tr>
<td>Overall (F = 62.2%, P &lt; 0.001)</td>
<td>0.85 (0.80–0.90)</td>
<td>Overall (F = 93.6%, P &lt; 0.001)</td>
<td>0.96 (0.94–0.98)</td>
</tr>
</tbody>
</table>

Figure 1.
Relative sensitivity (left) and speciﬁcity (right) of high-risk HPV DNA testing, using validated signal ampliﬁcation assays on self- versus clinician-collected samples to detect underlying cervical intraepithelial neoplasia of grade 2 or worse (updated from Arbyn et al., Lancet Oncol, 2014 [12]).
In conclusion, with the adoption of hrHPV testing for primary cervical cancer screening, self-sampling could be used to increase the participation of high-risk nonattendees in the cervical cancer screening program and thereby increase the effectiveness of the overall program. However, its introduction is not without important programmatic caveats and considerations. Only validated PCR-based HPV assays should be chosen. Before rolling out strategies involving HPV testing on self-samples, thorough planning is needed, and pilot studies should be conducted to assess the feasibility, costs, logistics, and population compliance in a given setting. Importantly, excellent follow-up of the screen-positives will be necessary to make this intervention for the nonattendees effective and cost-effective.

Disclosure of Potential Conflicts of Interest

P.E. Castle is CEO of Global Coalition Against Cervical Cancer; has speakers bureau honorarium from Cepheid and Roche; is a consultant/advisory board member for BD, Cepheid, ClearPath, GE Healthcare, Gesictel, Guided Therapeutics, Hologic, Inovio, Teva Pharmaceutical; and has provided expert testimony for Merck. No potential conflicts of interest were disclosed by the other author.

References


Figure 2.

Relative sensitivity (left) and specificity (right) of high-risk HPV DNA testing, using validated PCRs on self- versus clinician-collected samples to detect underlying cervical intraepithelial neoplasia of grade 2 or worse (updated from Arbyn et al, Lancet Oncol, 2014 [12]).

Authors’ Contributions

Conception and design: M. Arbyn, P.E. Castle
Development of methodology: M. Arbyn
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Arbyn
Writing, review, and/or revision of the manuscript: M. Arbyn, P.E. Castle

Acknowledgments

Ms. Freija Verdoodt is acknowledged for assistance in conducting the meta-analyses on HPV testing of self-samples.

Grant Support

M. Arbyn is supported by the seventh framework program of DG Research of the European Commission, through the COHEAHR Network (grant No. 603019), and the National Institute of Public Health and the Environment (Bilthoven, the Netherlands). P.E. Castle has received commercial HPV tests for research at a reduced or no cost from Roche, Qiagen, Norchip, Arbor Vita Corporation, BD, and mtm and has been compensated financially as a member of a Merck Data and Safety Monitoring Board for HPV vaccines.

Received January 13, 2015; revised February 13, 2015; accepted February 13, 2015; published OnlineFirst February 24, 2015.


Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program

Marc Arbyn and Philip E. Castle

Cancer Epidemiol Biomarkers Prev  Published OnlineFirst February 24, 2015.

Updated version  Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-14-1417

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://cebp.aacrjournals.org/content/early/2015/04/15/1055-9965.EPI-14-1417. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.